|
Basic Characteristics of Mutations
|
|
Mutation Site
|
F456L |
|
Mutation Site Sentence
|
Consistent with other work, we found significantly reduced activity against newer XBB descendants, notably EG.5, FL.1.5.1, and XBB.1.16, primarily attributed to the F456L spike mutation. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
EG.5;FL.1.5.1 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
39604453
|
|
Title
|
A deep learning approach predicting the activity of COVID-19 therapeutics and vaccines against emerging variants
|
|
Author
|
Matson RP,Comba IY,Silvert E,Niesen MJM,Murugadoss K,Patwardhan D,Suratekar R,Goel EG,Poelaert BJ,Wan KK,Brimacombe KR,Venkatakrishnan AJ,Soundararajan V
|
|
Journal
|
NPJ systems biology and applications
|
|
Journal Info
|
2024 Nov 27;10(1):138
|
|
Abstract
|
Understanding which viral variants evade neutralization is crucial for improving antibody-based treatments, especially with rapidly evolving viruses like SARS-CoV-2. Yet, conventional assays are labor intensive and cannot capture the full spectrum of variants. We present a deep learning approach to predict changes in neutralizing antibody activity of COVID-19 therapeutics and vaccine-elicited sera/plasma against emerging viral variants. Our approach leverages data of 67,885 unique SARS-CoV-2 Spike sequences and 7,069 in vitro assays. The resulting model accurately predicted fold changes in neutralizing activity (R(2) = 0.77) for a test set (N = 980) of data collected up to eight months after the training data. Next, the model was used to predict changes in activity of current therapeutic and vaccine-induced antibodies against emerging SARS-CoV-2 lineages. Consistent with other work, we found significantly reduced activity against newer XBB descendants, notably EG.5, FL.1.5.1, and XBB.1.16; primarily attributed to the F456L spike mutation.
|
|
Sequence Data
|
-
|
|
|